eClinical Technology and Industy News

Inflammasome Therapeutics’ Kamuvudines Continue to Show Promise for Future Treatment – and Potentially a Cure – for Blindness in Seniors

  • New research published today in Science Advances describes precise mechanism of how Alu reverse transcription occurs from RNA to cDNA, and its subsequent triggering of inflammasome activation and consequent cell death in Geographic Atrophy (GA) – the most severe form of dry age-related macular degeneration.
  • Research shows Alu RNA/cDNA reverse transcription confined to rim of lesions in human GA; new finding indicates potential to prevent activation of inflammasome activity and halt subsequent progression of GA.
  • Further confirms NRTIs and Kamuvudines block inflammasome activity and point to development of drugs to treat GA – potentially offering a cure for this eye condition where no therapeutic treatments are available

Excerpt from the Press Release:

NEWTON, Mass.–(BUSINESS WIRE)–Inflammasome Therapeutics (, a private company developing therapies for prevalent, degenerative diseases, reported new research conducted by a team of scientists led by Inflammasome’s co-founder Dr. Jayakrishna Ambati, and published today in Science Advances on Geographic Atrophy (GA), the most severe form of dry Age-related Macular Degeneration (AMD). In GA an area of the retinal pigmented epithelium (RPE, a layer of cells in the retina) becomes atrophied and the overlying sensory retina dies. Over time this area slowly spreads leading to blindness. It has been previously reported that Alu RNA is over expressed in the retinas of individuals with this condition. The paper confirms that in human eyes Alu RNA/cDNA conversion triggers inflammasome activity and resulting retinal cell death. Further, the paper shows that this process is confined to the rim of the lesion, indicating a potential for treatments to halt inflammasome activation and the progression of this disease to otherwise normal retina.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?